pembrolizumab + MK-4830 + carboplatin + pemetrexed

This is a **combination regimen** of four drugs commonly investigated for non-small cell lung cancer (NSCLC) and other advanced solid tumors. - **Pembrolizumab** is a humanized monoclonal antibody targeting the **PD-1 receptor** on T cells, enabling immune-mediated destruction of tumor cells. - **MK-4830** is a first-in-class monoclonal antibody targeting **immunoglobulin-like transcript 4 (ILT4)**, intended to alleviate myeloid cell-mediated immunosuppression in the tumor microenvironment[1][5]. - **Carboplatin** is a platinum-based chemotherapy agent that induces DNA crosslinking, leading to apoptosis in rapidly dividing cells. - **Pemetrexed** is an antifolate chemotherapy agent that inhibits several enzymes involved in purine and pyrimidine synthesis, resulting in inhibition of DNA replication in cancer cells[4]. This regimen works through both **checkpoint inhibition** and **cytotoxic chemotherapy** mechanisms, providing both immune-based and direct antineoplastic effects. It is primarily under investigation for the treatment of advanced solid tumors, notably metastatic nonsquamous NSCLC, and is used in clinical trials to explore enhanced antitumor efficacy through myeloid suppression combined with T-cell activation and cytotoxic activity[3][5].

Other names

pembrolizumabMK-4830MK4830MK 4830carboplatinpemetrexed